From December 1, 2015, David L Martin, chief executive officer of Cardiovascular Systems (CSI) will begin a medical leave of absence. He is due to take approximately three months to focus on treatment for cancer. The current chairman of the board of directors, Scott Ward, will serve as chairman and interim chief executive officer in his absence.
Martin says, “Scott’s extensive experience in medical technology and role as CSI Chairman makes him an excellent selection for interim Chief Executive Officer. With Scott and our executive management team’s leadership, I can concentrate on my remaining treatment and recovery. I plan to return as CEO in March 2016.”
Ward became a member of CSI’s board of directors in 2013 and was named chairman in November, 2014. He is a managing director at SightLine Partners, and the president of Raymond Holdings, positions that he will continue to hold. From 1981 to 2010, Ward was employed by Medtronic, and held a number of senior leadership positions including senior vice president and president of Medtronic’s cardiovascular business from May 2007 to November 2010.
“Dave has the full support of CSI and its board as he completes his treatment,” says Ward. “We wish him a quick recovery and look forward to his return. I look forward to working with the CSI team to advance the company as a leader in the treatment of calcified artery disease.”
